Alzheimer disease (AD) is the most common form of dementia. Pathologically, AD is characterized by amyloid plaques and neurofibrillary tangles in the brain, with associated loss of synapses and neurons, resulting in cognitive deficits and eventually deme
Targeting tau protein in Alzheimer's disease. Drugs & aging. 2010; 27 :351–365.Gong C. X., Grundke-Iqbal I., Iqbal K. (2010). Targeting tau protein in Alzheimer’s disease. Drugs Aging 27 351–365 10.2165/11536110-000000000-00000 [ Cross Ref ]...
Targeting tau for Alzheimer’s disease and related neurodegenerative disorders. Fall 2012By Dr HendersonDrug Discovery World
There is no effective treatment for Alzheimer's disease (AD) even though the prevalence of this neurodegenerative disorder and its associated costs are growing along with an ageing population. This article discusses whether tau could become a target for the development of disease modifying therapeutics...
Alzheimer's disease (AD) is a devastating neurodegenerative disease characterized by abnormal accumulation of tau proteins and amyloid-(3, leading to neuronal death and cognitive impairment. Recent studies have implicated aging pathways, including dysregulation of tau and cellular senescence in AD pathogen...
Tau plays a key role in Alzheimer’s disease (AD) pathophysiology, and accumulating evidence suggests that lowering tau may reduce this pathology. We sought to inhibit MAPT expression with a tau-targeting antisense oligonucleotide (MAPTRx) and reduce tau
BrightFocus Foundation. Tau Protein and Alzheimer’s Disease: What’s the Connection?https://www.brightfocus.org/alzheimers/article/tau-protein-and-alzheimers-disease-whats-connection. Accessed September 2023. Moumnéet al. Oligonucleotide Therapeutics: From Discovery and Development to Pa...
K Ubhi,E Masliah - 《Journal of Alzheimers Disease Jad》 被引量: 88发表: 2013年 Advances in the therapy of Alzheimer’s disease: targeting amyloid beta and tau and perspectives for the future Advances in the therapy of Alzheimer's disease: targeting amyloid beta and tau and perspectives for...
Episodic memory loss is a prominent clinical manifestation of Alzheimer’s disease (AD), which is closely related to tau pathology and hippocampal impairment. Due to the heterogeneity of brain neurons, the specific roles of different brain neurons in terms of their sensitivity to tau accumulation an...
Tau deposition in the brain is a pathological hallmark of many neurodegenerative disorders, including Alzheimer’s disease (AD). During the course of these tauopathies, tau spreads throughout the brain via synaptically-connected pathways. Such propagation of pathology is thought to be mediated by tau...